Structural Heart > TAVI Portfolio > ACURATE neo2 > Boston Scientific Clinical Studies


 

 

The 1st clinical review of the ACURATE neo2 Aortic Valve System with new Active PVseal™ sealing technology. 

STUDY DESIGN: N=120; European, prospective, single arm, multicenter study

Low device usage time, 3.9 minutes icon
High procedural success rates, 97.5 percent icon

PVL at 7 Days/Discharge, 30 Days, and 1 year1

CE mark trial
 

 

PRospective Observation of aortic reGuRgitation aftEr TAVI and progreSS over time (PROGRESS) PVL registry.

STUDY DESIGN: N=500; open-label, single arm, multicenter registry at 22 centers in
Germany, Canada, the United Kingdom, and Italy

 

PVL, Paired Analysis

progress pvl trial chard
 

 

Largest series, all-comers experience of ACURATE neo™ Aortic Valve System

STUDY DESIGN: N = 1,000; Real-world, European, prospective, single-arm, multicenter, all-comers registry

High procedural success rates, 97.5 percent icon
Low device usage time, 3.9 minutes icon
Zero coronary obstruction, 0.0% icon
Low PPI 8.3%, icon
complication rate icon
Low mean gradient, 4.4 mmHg icon
 

 
 

Sign Up

Get exclusive product updates, training and educational opportunities, and more.
Top